Update on the long-term complications of renal transplantation

British Medical Bulletin

Volumn 106, Issue 1, 2013, Pages 117-134

  Bottomley, Matthew J ^a   Harden, Paul N ^a  

^a CHURCHILL HOSPITAL   (United Kingdom)

Author keywords

cancer; cardiovascular; complications; kidney; long term; malignancy; renal; transplant dysfunction; transplantation

Indexed keywords

ACETYLSALICYLIC ACID; ALLOPURINOL; AMIODARONE; ANGIOTENSIN RECEPTOR ANTAGONIST; AZATHIOPRINE; BISPHOSPHONIC ACID DERIVATIVE; C REACTIVE PROTEIN; CALCIUM CHANNEL BLOCKING AGENT; CITALOPRAM; COLCHICINE; CORTICOSTEROID; CYCLOSPORIN; DIHYDROPYRIDINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EVEROLIMUS; FLUINDOSTATIN; FLUOXETINE; ISONIAZID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MACROLIDE; MYCOPHENOLIC ACID; PREDNISOLONE; PROTON PUMP INHIBITOR; RAPAMYCIN; RITUXIMAB; STEROID; SULFONYLUREA; TACROLIMUS; VITAMIN D;

ACUTE GRAFT REJECTION; ANXIETY; ATHEROSCLEROSIS; BACTERIAL ENDOCARDITIS; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CAUSE OF DEATH; CHICKENPOX; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL (TOPIC); DEPRESSION; DYSLIPIDEMIA; EDEMA; FRAMINGHAM RISK SCORE; GRAFT RECIPIENT; HEART INFARCTION; HEART LEFT VENTRICLE HYPERTROPHY; HEART MUSCLE REVASCULARIZATION; HEPATITIS B; HUMAN; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY ARTERY STENOSIS; KIDNEY CARCINOMA; KIDNEY TRANSPLANTATION; LYMPHOPROLIFERATIVE DISEASE; MENTAL HEALTH; MYCOSIS; NON MELANOMA SKIN CANCER; OPPORTUNISTIC INFECTION; OSTEOPOROSIS; PHENOTYPE; PNEUMONIA; PRACTICE GUIDELINE; PRIORITY JOURNAL; PSYCHOTHERAPY; QUALITY OF LIFE; REVIEW; SECONDARY PREVENTION; SUDDEN CARDIAC DEATH; TUBERCULOSIS; VITAMIN SUPPLEMENTATION; ARTICLE; BONE DISEASE; CARDIOVASCULAR DISEASE; INTERVENTION STUDY; MENTAL DISEASE; NEOPLASM; NONHUMAN; POPULATION; POSTOPERATIVE COMPLICATION; POSTOPERATIVE INFECTION; POSTTRANSPLANT LYMPHOPROLIFERATIVE DISEASE; RISK FACTOR; SYSTEMATIC REVIEW;

CANCER; CARDIOVASCULAR; COMPLICATIONS; KIDNEY; LONG-TERM; MALIGNANCY; RENAL; TRANSPLANT DYSFUNCTION; TRANSPLANTATION;

CARDIOVASCULAR DISEASES; HUMANS; IMMUNOCOMPROMISED HOST; IMMUNOSUPPRESSION; KIDNEY TRANSPLANTATION; NEOPLASMS; POSTOPERATIVE CARE; RISK FACTORS;

EID: 84878840905     PISSN: 00071420     EISSN: 14718391     Source Type: Journal    
DOI: 10.1093/bmb/ldt012     Document Type: Review

References (53)

1. Survival Rates Following Transplantation. http://www.organdonation.nhs. uk/ukt/statistics/transplant-activity-report/current-activity-reports/ukt/ survival-rates-following-transplantation.pdf. (18 September 2012, date last accessed).
2. Matas AJ, Smith JM, Skeans MA et al. OPTN/SRTR 2011 annual data report: kidney. Am J Transplant 2013;13(Suppl. 1):11-46.
3. Iordanous Y, Seymour N, Young A et al. Recipient outcomes for expanded criteria living kidney donors: the disconnect between current evidence and practice. Am J Transplant 2009;9:1558-73.
4. Moers C, Kornmann NS, Leuvenink HG et al. The influence of deceased donor age and old-for-old allocation on kidney transplant outcome. Transplantation 2009;88:542-52.
5. Segev DL. Renal allograft survival: getting better all the time. Am J Transplant 2011;11:422-3.
6. Traynor C, Jenkinson A, Williams Y et al. Twenty-year survivors of kidney transplantation. Am J Transplant 2012.
7. Matas AJ, Gillingham KJ, Humar A et al. 2202 kidney transplant recipients with 10 years of graft function: what happens next Am J Transplant 2008;8:2410-9.
8. Pilmore H, Dent H, Chang S et al. Reduction in cardiovascular death after kidney transplantation. Transplantation 2010;89:851-7.
9. US Renal Data System. USRDS 2012 annual data report: atlas of end-stage renal disease in the United States. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2012.
10. Israni AK, Snyder JJ, Skeans MA et al. Predicting coronary heart disease after kidney transplantation: patient outcomes in renal transplantation (PORT) study. Am J Transplant 2010;10:338-53.
11. Silver SA, Huang M, Nash MM et al. Framingham risk score and novel cardiovascular risk factors underpredict major adverse cardiac events in kidney transplant recipients. Transplantation 2011;92:183-9.
12. Weiner DE, Carpenter MA, Levey AS et al. Kidney function and risk of cardiovascular disease and mortality in kidney transplant recipients: the FAVORIT trial. Am J Transplant 2012;12:2437-45.
13. Svensson M, Jardine A, Fellstrom B et al. Prevention of cardiovascular disease after renal transplantation. Curr Opin Organ Transplant 2012;17:393-400.
14. Soveri I, Holme I, Holdaas H et al. A cardiovascular risk calculator for renal transplant recipients. Transplantation 2012;94:57-62.
15. Pita-Fernandez S, Pertega-Diaz S, Valdes-Canedo F et al. Incidence of cardiovascular events after kidney transplantation and cardiovascular risk scores: study protocol. BMC Cardiovasc Disord 2011;11:2.
16. Pilmore HL, Skeans MA, Snyder JJ et al. Cardiovascular disease medications after renal transplantation: results from the patient outcomes in renal transplantation study. Transplantation 2011;91:542-51.
17. Lentine KL, Villines TC, Xiao H et al. Cardioprotective medication use after acute myocardial infarction in kidney transplant recipients. Transplantation 2011;91:1120-6.
18. Cross NB, Webster AC, Masson P et al. Antihypertensives for kidney transplant recipients: systematic review and meta-analysis of randomized controlled trials. Transplantation 2009;88:7-18.
19. Clinical Management of Primary Hypertension in Adults (published 2011): http://guidance.nice.org.uk/CG127/NICEGuidance (13 February 2013, date last accessed).
20. Dantal J, Hourmant M, Cantarovich D et al. Effect of long-term immunosuppression in kidney-graft recipients on cancer incidence: randomised comparison of two cyclosporin regimens. Lancet 1998;351:623-8.
21. Gallagher MP, Kelly PJ, Jardine M et al. Long-term cancer risk of immunosuppressive regimens after kidney transplantation. J Am Soc Nephrol 2010;21:852-8.
22. Grulich AE, van Leeuwen MT, Falster MO et al. Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis. Lancet 2007;370:59-67.
23. Zwald FO, Brown M. Skin cancer in solid organ transplant recipients: advances in therapy and management: part I. Epidemiology of skin cancer in solid organ transplant recipients. J Am Acad Dermatol 2011;65:253-61; quiz 262.
24. Hoshida Y, Aozasa K. Malignancies in organ transplant recipients. Pathol Int 2004;54:649-58.
25. McLaughlin-Drubin ME, Meyers J, Munger K. Cancer associated human papillomaviruses. Curr Opin Virol 2012;2:459-66.
26. Ulrich C, Kanitakis J, Stockfleth E et al. Skin cancer in organ transplant recipients: where do we stand today Am J Transplant 2008;8:2192-8.
27. Ramsay HM, Reece SM, Fryer AA et al. Seven-year prospective study of nonmelanoma skin cancer incidence in U.K. renal transplant recipients. Transplantation 2007;84:437-9.
28. Euvrard S, Kanitakis J, Decullier E et al. Subsequent skin cancers in kidney and heart transplant recipients after the first squamous cell carcinoma. Transplantation 2006;81:1093-100.
29. Urwin HR, Jones PW, Harden PN et al. Predicting risk of nonmelanoma skin cancer and premalignant skin lesions in renal transplant recipients. Transplantation 2009;87:1667-71.
30. Carroll RP, Segundo DS, Hollowood K et al. Immune phenotype predicts risk for posttransplantation squamous cell carcinoma. J Am Soc Nephrol 2010;21:713-22.
31. Rini BI. Temsirolimus, an inhibitor of mammalian target of rapamycin. Clin Cancer Res 2008;14:1286-90.
32. Euvrard S, Morelon E, Rostaing L et al. Sirolimus and secondary skin-cancer prevention in kidney transplantation. N Engl J Med 2012;367:329-39.
33. Hoogendijk-van den Akker JM, Harden PN, Hoitsma AJ et al. A 2-year randomised controlled prospective trial converting stable renal transplant recipients with cutaneous invasive squamous cell carcinoma to sirolimus. J Clin Oncol 2013;31:1317-23.
34. Mihalis E, Wysong A, Boscardin WJ et al. Factors affecting sunscreen use and sun avoidance in a U.S. national sample of organ transplant recipients. Br J Dermatol 2012;168:346-53.
35. Zwald FO, Brown M. Skin cancer in solid organ transplant recipients: advances in therapy and management: part II. Management of skin cancer in solid organ transplant recipients. J Am Acad Dermatol 2011;65:263-79; quiz 280.
36. George R, Weightman W, Russ GR et al. Acitretin for chemoprevention of non-melanoma skin cancers in renal transplant recipients. Australas J Dermatol 2002;43:269-73.
37. Harwood CA, Leedham-Green M, Leigh IM et al. Low-dose retinoids in the prevention of cutaneous squamous cell carcinomas in organ transplant recipients: a 16-year retrospective study. Arch Dermatol 2005;141:456-64.
38. Vegso G, Hajdu M, Sebestyen A. Lymphoproliferative disorders after solid organ transplantation-classification, incidence, risk factors, early detection and treatment options. Pathol Oncol Res 2011;17:443-54.
39. Funch DP, Walker AM, Schneider G et al. Ganciclovir and acyclovir reduce the risk of posttransplant lymphoproliferative disorder in renal transplant recipients. Am J Transplant 2005;5:2894-900.
40. Jagadeesh D, Woda BA, Draper J et al. Post transplant lymphoproliferative disorders: risk, classification, and therapeutic recommendations. Curr Treat Options Oncol 2012;13:122-36.
41. Currie AC, Knight SR, Morris PJ. Tuberculosis in renal transplant recipients: the evidence for prophylaxis. Transplantation 2010;90:695-704.
42. Nankivell BJ, Kuypers DR. Diagnosis and prevention of chronic kidney allograft loss. Lancet 2011;378:1428-37.
43. Perl J, Zhang J, Gillespie B et al. Reduced survival and quality of life following return to dialysis after transplant failure: the dialysis outcomes and practice patterns study. Nephrol Dial Transplant 2012;27:4464-72.
44. Molnar MZ, Ojo AO, Bunnapradist S et al. Timing of dialysis initiation in transplant-naive and failed transplant patients. Nat Rev Nephrol 2012;8:284-92.
45. Alshayeb HM, Josephson MA, Sprague SM. CKD-mineral and bone disorder management in kidney transplant recipients. Am J Kidney Dis 2012;61:310-325.
46. KDIGO clinical practice guideline for the care of kidney transplant recipients. Am J Transplant 2009;9(Suppl. 3):S1-155.
47. Zelle DM, Dorland HF, Rosmalen JG et al. Impact of depression on long-term outcome after renal transplantation: a prospective cohort study. Transplantation 2012;94:1033-40.
48. Szeifert L, Molnar MZ, Ambrus C et al. Symptoms of depression in kidney transplant recipients: a cross-sectional study. Am J Kidney Dis 2010;55:132-40.
49. Spencer BW, Chilcot J, Farrington K. Still sad after successful renal transplantation: are we failing to recognise depression An audit of depression screening in renal graft recipients. Nephron Clin Pract 2011;117:c106-12.
50. Budde K, Matz M, Durr M et al. Biomarkers of over-immunosuppression. Clin Pharmacol Ther 2011;90:316-22.
51. Tullius SG, Tran H, Guleria I et al. The combination of donor and recipient age is critical in determining host immunoresponsiveness and renal transplant outcome. Ann Surg 2010;252:662-74.
52. Assessment of the Potential Kidney Transplant Recipient. Renal Association Guidelines (published 2011): http://www.renal.org/Clinical/ GuidelinesSection/AssessmentforRenalTrans plantation.aspx (15 November 2012, date last accessed).
53. Vajdic CM, McDonald SP, McCredie MR et al. Cancer incidence before and after kidney transplantation. JAMA 2006;296:2823-31.